Need all Congresses? Press Enter for expanded federal results.

HB 2520

Kansas House bill in Session 2025-2026.

Status: enacted. Latest action: April 9, 2026.

HB2520 - Increasing the number of allowed residents in a home plus facility from 12 to 16.

Bill ID KS-2025-2026-HB-2520
Session 2025-2026
Status enacted
Committee Public Health and Welfare
House enacted 2026-04-09
Summary

Increasing the number of allowed residents in a home plus facility from 12 to 16.

Sponsor
House Committee on Health and Human Services
Official Source Back to Bills
Actions Timeline
Date Event Detail
2026-01-22 Introduced Bill introduced
2026-04-09 Status enacted
2026-04-09 Latest Action Approved by Governor on 04-06-2026
More Bills From This Sponsor
HB 2365
HB2365 - Adding and removing certain substances in schedules I, III and IV of the uniform controlled substances act and making conforming changes to the criminal code definition of fentanyl-related controlled substances.
enacted • House
HB 2170
HB2170 - Designating the first full week of February as Kansas burn awareness week.
in_committee • House
HB 2763
HB2763 - Requiring school districts to provide elementary students with a certain amount of daily recess, prohibiting limiting or withholding recess for disciplinary reasons, requiring a Kansas state fitness test and designating required recess time as part of the school term.
vetoed • House
HB 2676
HB2676 - Permitting a pharmacist to initiate therapy for certain conditions consistent with the pharmacist's education, training and experience, adding pharmacists who initiate such therapy to the healthcare stabilization fund and allowing a pharmacist to dispense a one-time emergency refill of a noncontrolled prescription drug for up to a 90-day supply when no refills remain.
in_committee • House
HB 2587
HB2587 - Authorizing a licensed private psychiatric hospital to maintain a stock supply of emergency medication kits for pharmaceutical emergencies.
vetoed • House
HB 2364
HB2364 - Prohibiting certain health insurers from requiring cost-sharing for nonopioid prescription drugs or providing less favorable coverage for such drug than that for opioid or narcotic prescription drugs for the treatment of pain.
in_committee • House